Proactive Investors - Run By Investors For Investors

Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials

The study looks at the effectiveness of ampligen in combination with the drug pembrolizumab at treating ovarian cancer
cancer cells
Hemispherx believes that Ampligen could have anti-viral and anti-cancer properties

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) took a key step forward in its Phase 2 clinical trial on Wednesday after it announced that the first patient has been treated with its flagship drug Ampligen.

The study looks at the effectiveness of ampligen in combination with the drug pembrolizumab at treating ovarian cancer. It is being run out of the University of Pittsburgh Medical Center.

Shares of Hemispherx jumped 21.8% on Wednesday afternoon in New York.

READ: Hemispherx Biopharma’s well-funded to take promising cancer drug Ampligen through clinical trials

Florida-based Hemispherx believes that Ampligen could have anti-viral and anti-cancer properties. Prior clinical trials of the drug looked at patients with renal cell carcinoma and malignant melanoma.

The Phase 1 initial study indicated that Ampligen is generally well-tolerated when administrated through the abdominal cavity.

The Phase 2 clinical trials are being run under the leadership of principal investigator Dr. Robert Edwards and is expected to treat 45 patients.

Clinically significant

 “Ampligen has the potential to be clinically significant because a robust killer T-cell population in the tumor microenvironment without attracting Treg cells is important to help optimize checkpoint blockade induced tumor shrinkage," said Dr. Edwards in a statement.

Ovarian cancer is expected to be the cause of death for 152,000 people this year, according to Hemispherx.

“With this new large-scale study funded by an industry grant, Hemispherx and the team at Magee-Women's Hospital of the University of Pittsburgh School of Medicine are focused on developing a potentially life-saving therapy to meet this critical and unmet medical need," said CEO Thomas K. Equels.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full HEB profile View Profile

Hemispherx Biopharma Inc Timeline

Related Articles

skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Scientist at work
May 28 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use